Stewart Abbot

Company: Adicet Bio

Job title: Chief Scientific & Operating Officer

Bio:

Stewart Abbot is the chief scientific officer at Adicet Bio. He holds a B.Sc. in Biological Sciences (Edinburgh), M.Sc. in Biomedical Engineering (Glasgow) and Ph.D. in Pathology (London). His academic career focused on basic and translational science initiatives in vascular biology, pharmacology and toxicology. He joined Amersham Biosciences in 2000 and developed Amersham’s and, following acquisition, General Electric’s stem cell-based drug screening capabilities. He was head of the Molecular and Cellular Biology research laboratory at GE’s Global Research Center from 2004-2007. In 2007 he joined Celgene to develop novel cell-based therapeutic candidates and subsequently development of external cellular therapy R&D collaborations and alliances. In 2015 he joined Fate Therapeutics and held roles of VP translational research and chief development officer. He joined Adicet Bio. in June 2018 and his current role oversees all research associated with genetically engineered gamma delta T cell-based therapy development.

Seminars:

Maximizing the Clinical Potential of Gamma Delta T Cell-Based Therapies 12:30 pm

• Overview of manufacture of gene-modified gamma delta T cells • Understanding and optimizing activation pathways in gamma delta T cells • Optimizing the health and persistence of gamma delta T cell therapies and minimizing host versus graft responsesRead more

day: Day One